Literature DB >> 10648178

Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.

H Kaneko1, I Bednarek, A Wierzbicki, I Kiszka, M Dmochowski, T J Wasik, Y Kaneko, D Kozbor.   

Abstract

In this report, we described induction of HIV envelope (env)-specific systemic and mucosal immune responses by oral vaccination of BALB/c mice with env-encoded plasmid DNA encapsulated in poly(dl-lactide-co-glycolide) (PLG) microparticles. We demonstrated that intragastric administration of the encapsulated plasmid DNA resulted in transduced expression of the env glycoprotein in the intestinal epithelium. Mice immunized orally exhibited env-specific type 1 and cytotoxic T lymphocyte (CTL) responses in spleen and the inductive (Peyer's patches) and effector (lamina propria) mucosal tissues of gut. Oral administration of PLG-encapsulated plasmid DNA encoding gp160 also induced env-specific serum antibodies, and an increased level of IgA directed to gp160 was detected in fecal washes of the immunized mice. In contrast, intramuscular (i.m.) administration of naked or PLG-encapsulated DNA vaccine induced only systemic cellular and humoral responses to the env glycoprotein. Using an HIV env-expressing recombinant vaccinia viral intrarectal murine challenge system, we observed higher resistance to mucosal viral transmission in mice immunized orally than in animals injected i.m. with PLG-encapsulated plasmid DNA encoding gp160. Results of these studies demonstrate the feasibility of using orally delivered PLG microparticles containing plasmid DNA-encoded HIV gp160 for induction of env-specific systemic and mucosal immune responses and protection against recombinant HIV env vaccinia virus challenge. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10648178     DOI: 10.1006/viro.1999.0093

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  19 in total

Review 1.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

Review 2.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

3.  Chitosan-zein nano-in-microparticles capable of mediating in vivo transgene expression following oral delivery.

Authors:  Eric Farris; Deborah M Brown; Amanda E Ramer-Tait; Angela K Pannier
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

4.  Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.

Authors:  Toshio Naito; Yutaro Kaneko; Danuta Kozbor
Journal:  J Gen Virol       Date:  2007-01       Impact factor: 3.891

5.  Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaques.

Authors:  Thomas Musich; Thorsten Demberg; Ian L Morgan; Jacob D Estes; Genoveffa Franchini; Marjorie Robert-Guroff
Journal:  Clin Immunol       Date:  2015-04-01       Impact factor: 3.969

Review 6.  Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Expert Opin Biol Ther       Date:  2010-08       Impact factor: 4.388

7.  Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant.

Authors:  Noshin Kathuria; Kimberly A Kraynyak; Diane Carnathan; Michael Betts; David B Weiner; Michele A Kutzler
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

Review 8.  miRNAs in gastrointestinal diseases: can we effectively deliver RNA-based therapeutics orally?

Authors:  A K M Nawshad Hossian; Gerardo G Mackenzie; George Mattheolabakis
Journal:  Nanomedicine (Lond)       Date:  2019-11-18       Impact factor: 5.307

9.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

10.  Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine.

Authors:  Diane E Webster; Michelle L Cooney; Zhongjun Huang; Damien R Drew; Ian A Ramshaw; Ian B Dry; Richard A Strugnell; Jenny L Martin; Steve L Wesselingh
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.